Cargando…

Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study

BACKGROUND: While increasing coverage of effective vaccines against coronavirus disease 2019 (COVID-19), emergent variants raise concerns about breakthrough infection. Data are limited, however, whether breakthrough infection during the epidemic of the variant is ascribed to insufficient vaccine-ind...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamamoto, Shohei, Maeda, Kenji, Matsuda, Kouki, Tanaka, Akihito, Horii, Kumi, Okudera, Kaori, Takeuchi, Junko S, Mizoue, Tetsuya, Konishi, Maki, Ozeki, Mitsuru, Sugiyama, Haruhito, Aoyanagi, Nobuyoshi, Mitsuya, Hiroaki, Sugiura, Wataru, Ohmagari, Norio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755292/ https://www.ncbi.nlm.nih.gov/pubmed/34950947 http://dx.doi.org/10.1093/cid/ciab1048

Ejemplares similares

Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave
por: Yamamoto, Shohei, et al.
Publicado: (2023)

Cumulative and undiagnosed SARS-CoV-2 infection among the staff of a medical research centre in Tokyo after the emergence of variants
por: Mizoue, Tetsuya, et al.
Publicado: (2023)

Sensitivity of anti-SARS-CoV-2 nucleocapsid protein antibody for breakthrough infections during the epidemic of the Omicron variants
por: Mizoue, Tetsuya, et al.
Publicado: (2022)

Durability and determinants of anti-SARS-CoV-2 spike antibodies following the second and third doses of mRNA COVID-19 vaccine
por: Yamamoto, Shohei, et al.
Publicado: (2023)

Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
por: Yamamoto, Shohei, et al.
Publicado: (2023)

Seroprevalence of antibodies against SARS-CoV-2 in a large national hospital and affiliated facility in Tokyo, Japan
por: Tanaka, Akihito, et al.
Publicado: (2021)

Seroprevalence of SARS-CoV-2 antibodies in a national hospital and affiliated facility after the second epidemic wave of Japan
por: Yamamoto, Shohei, et al.
Publicado: (2021)

Sex‐associated differences between BMI and SARS‐CoV‐2 antibody titers following the BNT162b2 vaccine
por: Yamamoto, Shohei, et al.
Publicado: (2022)

Association of Impaired Fasting Glucose and Diabetes with SARS-CoV-2 Spike Antibody Titers after the BNT162b2 Vaccine among Health Care Workers in a Tertiary Hospital in Japan
por: Islam, Zobida, et al.
Publicado: (2022)

Association between γ-Glutamyl Transpeptidase and SARS-CoV-2 Spike Antibody Titers among BNT162b2 Vaccine Recipients
por: Islam, Zobida, et al.
Publicado: (2022)

Living with school-age children and absence among staff of a tertiary hospital during the Omicron epidemic in Tokyo
por: Yamamoto, S., et al.
Publicado: (2022)

SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal study
por: Takeuchi, Junko S., et al.
Publicado: (2022)

Infection prevention practices and its associated factors among hospital workers in a national medical center designated for COVID-19 in Tokyo, Japan
por: Manandhar Shrestha, Rachana, et al.
Publicado: (2022)

An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine
por: Khor, Seik-Soon, et al.
Publicado: (2022)

Green tea consumption and SARS-CoV-2 infection among staff of a referral hospital in Japan
por: Nanri, Akiko, et al.
Publicado: (2022)

Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan
por: Okumura, Nobumasa, et al.
Publicado: (2022)

Efficacy and Safety of Inhaled Ciclesonide in Treating Patients With Asymptomatic or Mild COVID-19 in the RACCO Trial: Protocol for a Multicenter, Open-label, Randomized Controlled Trial
por: Terada-Hirashima, Junko, et al.
Publicado: (2020)

Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine
por: Yamamoto, Shohei, et al.
Publicado: (2022)

Comparison of risk factors for SARS-CoV-2 infection among healthcare workers during Omicron and Delta dominance periods in Japan
por: Li, Y., et al.
Publicado: (2023)

Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan
por: Terada-Hirashima, Junko, et al.
Publicado: (2023)

Antibody responses and correlates after two and three doses of BNT162b2 COVID-19 vaccine
por: Yamamoto, Shohei, et al.
Publicado: (2022)

Analysis of Previous Infection, Vaccinations, and Anti–SARS-CoV-2 Antibody Titers and Protection Against Infection With the SARS-CoV-2 Omicron BA.5 Variant
por: Yamamoto, Shohei, et al.
Publicado: (2023)

Association between eating balanced meals and depressive symptoms in Japanese hospital workers during the COVID‐19 pandemic
por: Miki, Takako, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma
por: Maeda, Kenji, et al.
Publicado: (2021)

Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19
por: Miyazato, Yusuke, et al.
Publicado: (2022)

Association between engagement in COVID-19-related work and depressive symptoms among hospital workers in a designated COVID-19 hospital in Japan: a cross-sectional study
por: Inoue, Yosuke, et al.
Publicado: (2021)

Use of heated tobacco products, moderate alcohol drinking, and anti-SARS-CoV-2 IgG antibody titers after BNT162b2 vaccination among Japanese healthcare workers
por: Yamamoto, Shohei, et al.
Publicado: (2022)

Association between chronic physical conditions and depressive symptoms among hospital workers in a national medical institution designated for COVID-19 in Japan
por: Fukunaga, Ami, et al.
Publicado: (2022)

Social contact patterns in Japan in the COVID-19 pandemic during and after the Tokyo Olympic Games
por: Tsuzuki, Shinya, et al.
Publicado: (2022)

Autochthonous Dengue Fever, Tokyo, Japan, 2014
por: Kutsuna, Satoshi, et al.
Publicado: (2015)

Varicella in Adult Foreigners at a Referral Hospital, Central Tokyo, Japan, 2012–2016
por: Takaya, Saho, et al.
Publicado: (2020)

Metabolic syndrome and the immunogenicity of Pfizer–BioNTech vaccine: a cross-sectional study in Japanese healthcare workers
por: Van Hoang, Dong, et al.
Publicado: (2022)

A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy
por: Kamegai, Kohei, et al.
Publicado: (2022)

Efficacy and Safety of Direct Hemoperfusion Using Polymyxin B-Immobilized Polystyrene Column for Patients With COVID-19: Protocol for an Exploratory Study
por: Terada-Hirashima, Junko, et al.
Publicado: (2022)

Clinical characteristics and epidemiology of intestinal tapeworm infections over the last decade in Tokyo, Japan: A retrospective review
por: Tsuboi, Motoyuki, et al.
Publicado: (2018)

Validation of the severe COVID-19 prognostic value of serum IL-6, IFN-λ3, CCL17, and calprotectin considering the timing of clinical need for prediction
por: Yamamoto, Kei, et al.
Publicado: (2023)

Association of COVID-19-related discrimination with subsequent depression and suicidal ideation in healthcare workers
por: Narita, Zui, et al.
Publicado: (2023)

Underlying medical conditions and anti-SARS-CoV-2 spike IgG antibody titers after two doses of BNT162b2 vaccination: A cross-sectional study
por: Li, Jiaqi, et al.
Publicado: (2023)

Estimation of Organic Vapor Breakthrough in Humidified Activated Carbon Beds: -Application of Wheeler-Jonas Equation, NIOSH MultiVapor™ and RBT (Relative Breakthrough Time)
por: Abiko, Hironobu, et al.
Publicado: (2016)

Results of the Tokyo Consensus Meeting Tokyo Guidelines
por: Mayumi, Toshihiko, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_1ivke8ig03tbc9mj1ghfff9vik